This study investigates aliskiren, the first in a new antihypertensive class called renin inhibitors.
本试验中所研究的阿利·克伦是新一类降压药-肾素抑制剂的首种药物。
International Circulation: Finally, what is the present situation regarding clinical application of aliskiren in Europe?
国际循环：最后一个问题，阿利吉仑目前在欧洲的临床应用情况如何？
Aliskiren represents a new principle of blocking the RAAS, inhibiting renin directly and acting at the rate-limiting step.
阿利吉仑代表一种阻滞RAAS的新原理，直接抑制肾素并作用于限速阶段。
As I mentioned before, aliskiren has a very good profile for treating all types of hypertension throughout the entire spectrum.
正如我之前所提到的，阿利吉仑具有治疗全部疾病谱、各种类型高血压的很好记录。
Objectives: This dose-ranging study evaluated the antihypertensive efficacy and tolerability of aliskiren in patients with mild-to-moderate hypertension.
目的：本研究是评估阿利克伦在轻中度高血压患者中的有效及耐受剂量范围。
We compared the antiproteinuric effect of maximal recommended doses of aliskiren, irbesartan, and the combination in patients with type 2 diabetes and albuminuria.
我们比较了最大推荐剂量的阿利吉仑、依贝沙坦及两者联合应用在2型糖尿病和蛋白尿患者的抗蛋白尿作用。
Conclusions: Aliskiren provides significant antihypertensive efficacy in patients with hypertension, with no rebound effects on blood pressure after treatment withdrawal.
结论：阿利克伦显著降低高血压患者血压，停药后血压不会反跳。
OBJECTIVE We investigated whether the antiproteinuric effect of the direct renin inhibitor aliskiren is comparable to that of irbesartan and the effect of the combination.
目的我们研究直接肾素抑制剂阿利吉仑的抗蛋白尿作用是否与依贝沙坦相当及两者联合的效果。
International Circulation: We know that the effect of aliskiren on organ damage and clinical outcomes is being assessed in clinical trials such as the ASPIRE Higher program.
国际循环：我们知道，阿利吉仑对器官损伤的作用，而诸如aspireHIGHER项目等临床试验中则正在对临床转归进行评价。
These findings suggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy.
这些结果表明阿里克伦在减轻高血压合并左室肥厚患者心脏终末损伤方面，与血管紧张素受体阻滞剂的效果类似。
These findings suggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy.
这些结果表明阿里克伦在减轻高血压合并左室肥厚患者心脏终末损伤方面，与血管紧张素受体阻滞剂的效果类似。
应用推荐